Akouos, Inc.(NASDAQ : AKUS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||7.14%||12.90||0.7%||$901.76m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.75%||186.95||1.9%||$493.62m|
|GILD||Gilead Sciences, Inc.||-1.55%||66.18||1.0%||$472.89m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.33%||534.27||2.7%||$373.82m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.43%||179.20||2.0%||$335.86m|
|EXAS||EXACT Sciences Corp.||-1.23%||125.35||18.1%||$188.43m|
|TXG||10X Genomics, Inc.||-1.80%||195.19||0.0%||$168.07m|
|IOVA||Iovance Biotherapeutics, Inc.||-1.38%||24.28||0.0%||$167.80m|
Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA.